Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dofila Joint Support
- Development stage
- Unknown
- Lead developer
- Aranex
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dofila Joint Support is an oral veterinary nutritional supplement developed by Percos under its Aranex brand for dogs and cats. Formulated as a tablet, it contains a combination of glucosamine, chondroitin, and methylsulfonylmethane (MSM). These ingredients serve as essential building blocks for joint cartilage and connective tissue, helping to maintain cartilage elasticity, support joint lubrication, and reduce inflammation. Dofila Joint Support is indicated for the management of joint stiffness, osteoarthritis, hip dysplasia, and age-related mobility issues in companion animals.
- Brand names
- Dofila Joint Support
- Other names
- Aranex Dofila Joint Support TabletDofila Joint Support Tablet
Beyond the preview
Go deeper on Dofila Joint Support.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dofila Joint Support.